Trials / Completed
CompletedNCT04581629
Safety, Tolerability, and Efficacy of Encaleret in Participants With Autosomal Dominant Hypocalcemia (ADH) Type 1
A Phase 2b, Open-label Dose-ranging Study Evaluating the Safety, Tolerability, Pharmacodynamics and Pharmacokinetics, and Efficacy of CLTX-305 (Encaleret) in Autosomal Dominant Hypocalcemia (ADH) Type 1
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 13 (actual)
- Sponsor
- Calcilytix Therapeutics, Inc., a BridgeBio company · Industry
- Sex
- All
- Age
- 16 Years
- Healthy volunteers
- Not accepted
Summary
The primary purpose of this study is to evaluate the safety, tolerability and effectiveness of encaleret in participants with Autosomal Dominant Hypocalcemia Type 1 (ADH1).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Encaleret | Tablets administered orally |
Timeline
- Start date
- 2020-09-20
- Primary completion
- 2023-09-07
- Completion
- 2023-09-07
- First posted
- 2020-10-09
- Last updated
- 2024-11-19
- Results posted
- 2024-11-19
Locations
1 site across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT04581629. Inclusion in this directory is not an endorsement.